Enristomig Biosimilar – Anti-Tumor necrosis factor receptor superfamily member 9; CD274 mAb – Research Grade

Description of Enristomig Biosimilar - Anti-Tumor necrosis factor receptor superfamily member 9; CD274 mAb - Research Grade

Introduction

Enristomig Biosimilar is a research grade antibody that targets the tumor necrosis factor receptor superfamily member 9 (TNFRSF9) and CD274, also known as programmed death-ligand 1 (PD-L1). This biosimilar is a monoclonal antibody (mAb) that has been developed as a therapeutic agent for the treatment of various diseases, particularly cancer. In this article, we will discuss the structure, activity, and potential applications of Enristomig Biosimilar in detail.

Structure of Enristomig Biosimilar

Enristomig Biosimilar is a recombinant humanized IgG1 monoclonal antibody that is produced using Chinese hamster ovary (CHO) cells. It has a molecular weight of approximately 150 kDa and is composed of two identical heavy chains and two identical light chains. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of two constant domains (CL and CL’) and one variable domain (VL). The variable domains of both heavy and light chains are responsible for binding to the target molecules, TNFRSF9 and CD274.

Activity of Enristomig Biosimilar

Enristomig Biosimilar specifically targets TNFRSF9 and CD274, which are important therapeutic targets for the treatment of cancer. TNFRSF9 is a member of the tumor necrosis factor receptor (TNFR) superfamily, which is involved in the regulation of immune responses and cell survival. It is expressed on the surface of various immune cells, including T cells, B cells, and natural killer cells. Binding of TNFRSF9 to its ligand, TNF-like ligand 1A (TL1A), activates downstream signaling pathways that promote cell proliferation and survival. However, overexpression of TNFRSF9 has been observed in many types of cancer, leading to uncontrolled cell growth and tumor progression.

On the other hand, CD274 is a transmembrane protein that is expressed on the surface of various cells, including cancer cells. It binds to its receptor, programmed cell death protein 1 (PD-1), and inhibits the activity of immune cells, allowing cancer cells to evade the immune system. This mechanism is known as immune checkpoint blockade and is a major target for cancer immunotherapy. By targeting CD274, Enristomig Biosimilar can block this inhibitory signaling pathway and enhance the anti-tumor immune response.

Applications of Enristomig Biosimilar

Enristomig Biosimilar has shown promising results in preclinical studies as a therapeutic agent for the treatment of various types of cancer. It has been shown to inhibit the growth of cancer cells and induce cell death in both in vitro and in vivo models. Additionally, in combination with other anti- cancer therapies, Enristomig Biosimilar has demonstrated synergistic effects, leading to improved efficacy.

Enristomig Biosimilar is currently being evaluated in clinical trials for the treatment of different types of cancer, including melanoma, non-small cell lung cancer, and head and neck cancer. Preliminary results from these trials have shown promising anti-tumor activity and a favorable safety profile. If approved, Enristomig Biosimilar has the potential to become an important treatment option for cancer patients.

Conclusion

Enristomig Biosimilar is a research grade antibody that targets TNFRSF9 and CD274, two important therapeutic targets for the treatment of cancer. It has a well-defined structure and exhibits specific activity against these targets. Enristomig Biosimilar has shown promising results in preclinical and clinical studies and has the potential to become an important treatment option for cancer patients. Further research and clinical trials are needed to fully understand the potential of this biosimilar in the treatment of cancer.